Search
AZD2389
go.drugbank.com/drugs/DB22104InvestigationalAZD2389 is an investigational small molecule inhibitor of fibroblast activation protein (FAP).[L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g. … NCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants).
WNY0824
go.drugbank.com/drugs/DB23606Experimental[A274253] It is a dual inhibitor of PLK-1 and BRET-4, which have both been found to be involved in CRPC via suppression of AR/MYC-mediated transcription. [A274258] … WNY0824 is a preclinical small molecule drug being investigated for the treatment of Castration-Resistant Prostrate Cancer (CRPC).
Synonyms: PLK1/BRD4-IN-1PHB-050
go.drugbank.com/drugs/DB32061ExperimentalPHB-050 is a novel, next-generation anti-IgE antibody designed to block IgE from binding to mast cells, while also rapidly reducing circulating IgE and inhibiting its production. … [L54988] It is under investigation for the treatment of multiple atopic diseases, including food allergies, asthma, and atopic dermatitis.[L54988]
TS-104
go.drugbank.com/drugs/DB33943ExperimentalTS-104 is a biologic drug. … TS-104 is under investigation in clinical trial NCT07814248 (A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy
WIN 55212-2
go.drugbank.com/drugs/DB13950ExperimentalIt is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of neuropathic pain. It activates p42 and p44 MAP kinase via receptor-mediated signaling. … WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical
Salts: WIN 55212-2 mesylateCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingAnti-SARS-CoV-2 immunoglobulin
go.drugbank.com/drugs/DB16360InvestigationalHyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies. … [L27521] Anti-coronavirus immunoglobulin is derived from [COVID-19 convalescent plasma](https://go.drugbank.com/drugs/DB15692) but contains more SARS-CoV-2 neutralizing antibodies than found in [convalescent
Categories: Immunoglobulin GSynonyms: SARS-CoV-2 immunoglobulin, SARS-CoV-2 antibody-based IVIG1-Deoxy-D-xylulose 5-phosphate
go.drugbank.com/drugs/DB02496ExperimentalThe proteins that 1-Deoxy-D-xylulose 5-phosphate targets include 1-Deoxy-D-xylulose 5-phosphate reductoisomerase and pyridoxine 5'-phosphate synthase. 1-Deoxy-D-xylulose 5-phosphate is an intermediate … 1-Deoxy-D-xylulose 5-phosphate is a solid. This compound belongs to the pentose phosphates. These are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups.
Synonyms: 1-Deoxy-D-xylulose 5-phosphateAMT-080
go.drugbank.com/drugs/DB17846ExperimentalAMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.
NGGT-002
go.drugbank.com/drugs/DB17881InvestigationalNGGT-002 is a recombinant adeno-associated virus serotype 8 vector encoding human phenylalanine hydroxylase (PAH).
PLG-0206
go.drugbank.com/drugs/DB18116InvestigationalPLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.[L48106]